Evidence map›Paper›PMID 30069753›Full record

ArticleEJNMMI research2018

Whole tumor kinetics analysis of

Daniel R McGowan, Michael Skwarski, Bartlomiej W Papiez, Ruth E Macpherson, Fergus V Gleeson, Julia A Schnabel, Geoff S Higgins, John D Fenwick

Abstract read
In one paragraph

Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel R McGowanDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK. daniel.mcgowan@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0002-6880-5687
Michael SkwarskiDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Bartlomiej W PapiezInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Ruth E MacphersonDepartment of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Fergus V GleesonDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Julia A SchnabelSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Geoff S HigginsDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
John D FenwickDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.

Funding

Cancer Research UK 13092Cancer Research UK 15163Cancer Research UK 16466Cancer Research UK 19590Cancer Research UK C17203Cancer Research UK C34326/A13092Cancer Research UK CRUKD/12/016Department of Health ICA-CL-2016-02-009
6 · The paper itself

Abstract

backgroundTo determine the relative abilities of compartment models to describe time-courses of 18F-fluoromisonidazole (FMISO) tumor uptake in patients with advanced stage non-small cell lung cancer (NSCLC) imaged using dynamic positron emission tomography (dPET), and study correlations between values of the blood flow-related parameter K

resultsAn irreversible three-tissue compartment model provided the best description of whole tumor FMISO uptake time-courses according to AIC, BIC, and cross-validation scores totaled across the TACs. The simulation study indicated that this model also provided more precise estimates of FMISO uptake kinetics than other two- and three-tissue models. The K

conclusionsTime-courses of whole tumor FMISO uptake by advanced stage NSCLC are described best by an irreversible three-tissue compartment model. The K

Indexed as

Dynamic PETFMISOKinetics analysisNSCLCPerfusion CT

Identifiers

PMID30069753
PMCPMC6070455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.